bims-fagtap Biomed News
on Phage therapies and applications
Issue of 2025–10–19
37 papers selected by
Luca Bolliger, lxBio



  1. Front Cell Infect Microbiol. 2025 ;15 1668727
      The prevalence of multidrug-resistant Klebsiella pneumoniae (K. pneumoniae) poses a severe threat to the global economy and public health, driving a resurgence of interest in phage therapy. Consequently, it is imperative to isolate lytic phages against K. pneumoniae with potent bactericidal activity. This study reports the isolation and characterization of the phage HHU1 against K. pneumoniae from hospital sewage, to evaluate its potential for phage therapy. Phage HHU1 has an icosahedral head and retractable tail, similar to members of the Jedunavirus genus. Host range tests revealed that phage HHU1 obligately lysed K. pneumoniae of the K2 serotype. Genome sequencing analysis showed that the genome of phage HHU1 was 47,779 bp in length, with a GC content of 49.2%, encoding 78 open reading frames, and lacked genes associated with lysogeny and virulence. The rapid adsorption (8 min), short latent period (10 min), and high burst size (approximately 134 PFU/cell) indicate robust replication kinetics of phage HHU1. Phage HHU1 remained stably active even after incubation for 6 h at pH 5.0-10.0 and temperature 4-40°C. In addition, phage HHU1 with different MOIs can completely inhibit the growth of drug-resistant K. pneumoniae within 8 h in vitro and significantly reduce biofilm formation of drug-resistant bacteria. Notably, treatment with high-dose phage HHU1 (MOI = 0.1 and 1) achieved 100% survival in Galleria mellonella larvae infected with drug-resistant K. pneumoniae. These findings demonstrate the potential of phage HHU1 as a promising therapeutic candidate against drug-resistant K. pneumoniae infections.
    Keywords:  Klebsiella pneumoniae; biological properties; drug-resistant; phage HHU1; phage therapy
    DOI:  https://doi.org/10.3389/fcimb.2025.1668727
  2. Eur J Clin Microbiol Infect Dis. 2025 Oct 17.
       PURPOSE: The global rise in multidrug-resistant (MDR) Klebsiella pneumoniae, a critical ESKAPE pathogen, has outpaced the development of effective antibiotics. Bacteriophage therapy offers a promising alternative, but therapeutic candidates must be carefully selected for broad activity, genetic safety, synergistic cocktail performance, and clinical stability.
    METHODS: We isolated and characterized six novel lytic phages (vB_Kpn_AM.K1 to vB_Kpn_AM.K6) targeting K. pneumoniae by assessing morphology, host range, growth kinetics, physicochemical stability, and resistance frequency. Genomes were sequenced to confirm absence of lysogeny and virulence genes. Infection dynamics was visualized via fluorescence microscopy. Phage activity was tested across 60 different MDR K. pneumoniae clinical isolates, obtained from diverse sources such as blood, sputum, occult feces, urine etc. RESULTS: All six isolated phages were identified as novel dsDNA phages belonging to Caudoviricetes, with genome sizes ranging from 111 to 169 Kbp, devoid of virulence and AMR genes and demonstrating strong bacteriolytic activity. Growth kinetics indicated burst sizes varying from 12-148 PFU/infected cell. The phages displayed stability between 4-50°C, pH 4 -10 and sustained complete activity after lyophilization. More significantly, the phages and their cocktail combinations could effectively kill 93% of MDR K. pneumoniae clinical isolates.
    CONCLUSION: These findings establish a panel of genetically safe, phenotypically diverse phages with broad and synergistic activity against MDR K. pneumoniae. The unique replication phenotypes and formulation stability highlight their potential for therapeutic development and deployment in clinical or resource-limited settings.
    Keywords:   Klebsiella pneumoniae ; ESKAPE pathogens; Intracellular replication dynamics; Multidrug resistance; Phage cocktail
    DOI:  https://doi.org/10.1007/s10096-025-05300-8
  3. Bioinform Adv. 2025 ;5(1): vbaf239
       Motivation: Phage therapy is emerging as a promising alternative to antibiotics in biomedical research, highlighting the growing need for computational tools to rationally design effective phage cocktails. However, its clinical potential is often compromised by the evolution of heritable bacterial resistance, which is frequently exacerbated by repeated phage exposure. This can lead to broad-spectrum cross-resistance and reduced long-term efficacy. Existing approaches typically rely on host range matrices but often overlook viral interference and the complex, non-binary nature of virus-host interactions.
    Results: We present SocialViruses, a tool for designing optimized phage cocktails selecting up to twelve viruses and using two alternative algorithms. SocialViruses integrates quantitative host range infection and virus-virus interaction matrices to guide cocktail design. It produces a detailed report with key quality metrics and allows users to define multiple cocktails while minimizing viral interference and managing co-infection redundancy.
    Availability and implementation: SocialViruses is freely available as a Cytoscape application and can be downloaded from: https://apps.cytoscape.org/apps/SocialViruses.
    DOI:  https://doi.org/10.1093/bioadv/vbaf239
  4. Periodontol 2000. 2025 Oct 14.
       BACKGROUND: Antibiotics marked a pivotal turning point in human civilization, enhancing social interactions and extending human life expectancy. In addition to their success in treating systemic infectious diseases, they have significantly improved periodontal treatment outcomes as an adjunct therapy. The current status of systemic antibiotics in periodontal therapy is well established. However, antibiotic-resistant bacteria emerged as a result of their overuse and misuse. It is estimated that by 2050, infections caused by multidrug-resistant bacteria could result in the deaths of 10 million people annually. Beyond promoting the expansion of resistant species, broad-spectrum antimicrobials also eliminate commensal microorganisms and disrupt the microbial balance in distant organs, both of which are essential for maintaining overall health.
    AIM: This narrative review acknowledges how the use of systemic antibiotics has contributed to our understanding of the role of microbial factors as therapeutic targets, presents novel and emerging technologies that will advance the field, and highlights emerging strategies aimed at eliminating oral disease-related microbial species without inducing antimicrobial resistance or causing dysbiosis in distant parts of the body.
    MATERIALS AND METHODS: A literature search of the National Library of Medicine (MEDLINE/PubMed) database was conducted to identify publications related to new and developing antimicrobial approaches for treating oral infections without triggering antibiotic resistance or creating dysbiosis in other parts of the body.
    RESULTS: Previous studies suggest that targeted antimicrobials directed against oral pathobionts and locally effective antibiotics applied at disease sites are potential strategies to reduce the large-scale emergence of antimicrobial resistance and minimize microbiota disruption. Selective action is fundamental to the development of a targeted antimicrobial strategy: An ideal antimicrobial treatment should be highly specific to pathogenic microorganisms without harming the host or its commensal microbiota. In addition to targeted antibiotics and localized drug delivery systems, probiotics, antibodies, phage therapy, photodynamic therapy, and vaccination are promising approaches for addressing the issues associated with broad-spectrum antibiotics.
    FUTURE DIRECTIONS: The WHO has recommended a global action plan that calls for the development of novel antimicrobials or innovative therapeutic approaches for infectious diseases. New methods are required, extensive education programs should be offered worldwide, and stricter criteria for dental antibiotics should be developed using a comprehensive approach.
    Keywords:   Fusobacterium nucleatum ; Antimicrobial agents; dysbiosis; microbial drug resistance; oral microbiome; periodontal diseases; species‐specific antibiotics
    DOI:  https://doi.org/10.1111/prd.70015
  5. Infect Agent Cancer. 2025 Oct 14. 20(1): 70
      There is growing evidence that Fusobacterium nucleatum, a Gram-negative anaerobic bacterium found in the gut and oropharynx, is a key player in the pathogenesis of colorectal cancer (CRC), by promoting tumor progression, immune evasion, and drug resistance. Despite the effectiveness of antibiotic regimens in reducing F. nucleatum abundance, concerns about antimicrobial resistance and gut dysbiosis limit the use of these drugs for a long period of time. Antimicrobial peptides (AMPs), bacteriophage therapy, and immune-based interventions all offer promising alternatives to conventional treatments. Checkpoint inhibitors and microbiome-based immunotherapy may also enhance antitumor immunity by alleviating F. nucleatum-induced immunosuppression. Furthermore, multimodal strategies, including dietary interventions and engineered probiotics, can help manage F. nucleatum-associated CRC holistically. It has been shown that probiotics can modulate gut microbiota composition and reduce F. nucleatum colonization by using strains of Lactobacillus and Bifidobacterium. This has led to improved outcomes for CRC patients by targeting this bacterium. In addition, preclinical evidence indicates that certain peptide-based antimicrobials can target F. nucleatum biofilms, though their specificity for pathogenic over commensal bacteria. Phage therapy, for instance, selectively targets the bacterium without harming others. But, to ensure efficacy and safety, clinical trials and mechanistic studies should be undertaken to optimize these therapeutic strategies. Understanding F. nucleatum's role in CRC and refining targeted interventions can help researchers develop innovative strategies to prevent and treat CRC. The purpose of this review is to examine current and emerging approaches to combating F. nucleatum in CRC, with a particular focus on probiotics, antibiotics, and alternative therapies.
    Keywords:   Fusobacterium nucleatum ; Colorectal cancer (CRC); Gut microbiome; Microbiome-based therapy; Probiotics and antibiotics
    DOI:  https://doi.org/10.1186/s13027-025-00676-w
  6. Npj Viruses. 2025 Oct 16. 3(1): 73
      Multidrug-resistant (MDR) Shigella spp. threaten global health, renewing interest in phage therapy. Here, we report the isolation and characterization of a novel lytic phage, SSG23, effective against four major Shigella serovars. Phage SSG23 possesses a prolate head and contractile tail, consistent with the Straboviridae family, and remains stable across a broad pH (4-11) and temperature range (-20 °C to 50 °C). It exhibits a latent period of 37 minutes, a burst size of 195 plaque-forming units per cell, and a 168,820 bp dsDNA genome with 40.8% GC content lacking resistance or toxin genes. SSG23 efficiently degrades biofilms, alone or with antibiotics, and is non-toxic to macrophages in vitro. In S. sonnei-infected BALB/c mice, oral administration reduced bacterial colonization and shedding while improving health without evidence of resistance emergence. Neutralizing antibodies developed in mice, yet the phage maintained its efficacy. These findings support SSG23 as a promising candidate for phage therapy against Shigella infection.
    DOI:  https://doi.org/10.1038/s44298-025-00155-4
  7. Folia Microbiol (Praha). 2025 Oct 15.
      The growing emergence of antibiotic resistance has prompted the World Health Organization to include Escherichia coli on its list of global priority pathogens, highlighting the urgent need for new therapeutic strategies. This study was designed to isolate and characterize phage(s) against multidrug-resistant (MDR) E. coli and to evaluate their potential for inhibiting biofilms. Phages were isolated from hospital sewage and screened against 18 prophage-free clinical MDR E. coli isolates. Two phages, R8 and R9, were selected for further characterization. Their host range, efficiency of plating, one-step growth curve, and morphology were determined via transmission electron microscopy. The biofilm inhibitory efficacy of each phage, both individually and as a two-phage cocktail, was quantified using a microtiter plate assay. Two isolated bacteriophages, R8 and R9, belonging to the class Caudoviricetes, were identified. Both phages demonstrated a lytic spectrum against 38.8% of the tested MDR isolates. They exhibited short latent periods (20-22 min), with R9 displaying a significantly larger burst size (300 PFU/cell) than R8 (130 PFU/cell). Notably, phage R9, when applied alone, showed significantly superior biofilm inhibition compared to both phage R8 and the phage cocktail across various MOIs. The relatively broad host range, short latent phase, suitable burst size, and biofilm inhibitory effect demonstrate the potential of both phages-especially R9-for further analysis and consideration as candidates for therapeutic applications.
    Keywords:   Escherichia coli ; Bacteriophage; Biofilm; Multidrug-resistant infection; Phage therapy
    DOI:  https://doi.org/10.1007/s12223-025-01347-4
  8. Appl Environ Microbiol. 2025 Oct 15. e0159825
      With the increasing importance of alternative pesticides for the control of bacterial pathogens in agricultural and clinical settings, the use of bacteriophage viruses (phages) to reduce bacterial growth and prevent disease is gaining in popularity. Phages have been shown to be highly effective in killing bacterial cells both in vitro and across plant and animal host systems, although many questions remain about the predictability of their success across more realistic ecological conditions and in light of natural strain variation of pathogens. Furthermore, as phage application becomes more common, it is imperative that we better understand the consequences of these treatments on the microbial communities associated with hosts (i.e., their microbiomes). Here, we leverage a recently developed phage cocktail targeting the causal agent of fire blight disease, Erwinia amylovora, to both test the efficacy of these phages in pear flowers inoculated with the pathogen and to ask whether such application has adverse effects on the resident microbiome of flowers. We found that phages are capable of greatly reducing both pathogen numbers and disease symptoms, but their application does not significantly alter the floral microbiome, emphasizing their high specificity to their target host. These data support the safe and effective use of phages in this disease system.IMPORTANCEThere is a critical need to develop new strategies to control bacterial diseases in crops, particularly to address the emerging problem of fire blight in pomme fruit. Bacteriophages, as viruses that infect and kill bacteria, are an appealing strategy. However, there is little information on how these viruses are impacting natural microbial communities, their potential off-target effects, and their environmental safety. This study addresses these questions, looking at the impact of an effective phage cocktail targeting Erwinia amylovora, the causal agent of fire blight in pomme fruit. In our research, we demonstrated that our phage cocktail does not affect the natural floral microbiome of Bradford pear blossoms. We further found that in the presence of E. amylovora, our phage cocktail significantly increases the richness and diversity of the microbial community. Our data, together with other studies performed in parallel, add to the small but growing evidence that phage application is unlikely to have an impact beyond the target bacterial pathogens they are used to treat.
    Keywords:  bacteriophage; biological control; fire blight; microbiome
    DOI:  https://doi.org/10.1128/aem.01598-25
  9. Arch Microbiol. 2025 Oct 18. 207(12): 310
      Phage therapy is a promising approach against multidrug-resistant infections, yet systemic administration can lead to incomplete cures. We investigated the distribution, immune responses, and efficacy of the therapeutic phage KPP10 delivered via intranasal or intraperitoneal (IP) routes in murine Pseudomonas aeruginosa lung infection models. Intranasal pre-treatment achieved markedly higher localization of KPP10 in the lungs and bronchoalveolar compartment compared to IP delivery. Intranasal administration elicited minimal systemic antibody responses, whereas IP injection triggered significant IgG, IgM, and IgA production. Antibody responses did not differ significantly between doses. In acute and chronic infection models, intranasal KPP10 significantly improved survival (p < 0.01) and reduced lung bacterial loads relative to IP injection. Importantly, IP treatment was associated with bacterial rebound after day 14 in chronic infection, whereas intranasal dosing sustained bacterial clearance. These findings demonstrate that intranasal delivery enhances pulmonary localization, minimizes antibody-mediated neutralization, and provides superior therapeutic efficacy, highlighting its potential as a more effective route for phage therapy against P. aeruginosa lung infections.
    Keywords:  Antibody-mediated neutralization; Chronic pulmonary Pseudomonas aeruginosa infections; Intranasal phage treatment
    DOI:  https://doi.org/10.1007/s00203-025-04526-6
  10. Nat Commun. 2025 Oct 14. 16(1): 9114
      Bacteriophages, viruses infecting bacteria, are estimated to outnumber their cellular hosts by 10-fold, acting as key players in all microbial ecosystems. Under evolutionary pressure by their host, they evolve rapidly and encode a large diversity of protein sequences. Consequently, the majority of functions carried by phage proteins remain elusive. Current tools to comprehensively identify phage protein functions from their sequence either lack sensitivity (those relying on homology for instance) or specificity (assigning a single coarse grain function to a protein). Here, we introduce Empathi, a protein-embedding-based classifier that assigns functions in a hierarchical manner. New categories were specifically elaborated for phage protein functions and organized such that molecular-level functions are respected in each category, making them well suited for training machine learning classifiers based on protein embeddings. Empathi outperforms homology-based methods on a dataset of cultured phage genomes, tripling the number of annotated homologous groups. On the EnVhogDB database, the most recent and extensive database of metagenomically-sourced phage proteins, Empathi doubled the annotated fraction of protein families from 16% to 33%. Having a more global view of the repertoire of functions a phage possesses will assuredly help to understand them and their interactions with bacteria better.
    DOI:  https://doi.org/10.1038/s41467-025-64177-5
  11. Crit Rev Microbiol. 2025 Oct 15. 1-19
      Human fungal infections are increasingly being recognized as a significant global health threat. The burden of fungal diseases is escalating, primarily due to the rising number of at-risk individuals, compounded by the limited availability of antifungal therapies that are both effective and minimally toxic. Phages, viruses that specifically infect and kill bacteria, have long been investigated for their therapeutic potential. However, despite their success in bacteriology, the applications of phages in antifungal therapy are under active research. Particularly, phages could be used to treat fungal infections by engineering them to express fungal antigens on their surfaces, and this would trigger specific immune responses, such as activating Th1 and Th17 responses or inducing the production of neutralizing antibodies. Phages could also be combined with photodynamic inactivation (PDI) or antimicrobials to enhance treatment efficiency. Meanwhile, phages can exert direct antifungal effects by depleting iron, a crucial nutrient for fungal growth. This paper provides a comprehensive review of the phage-based antifungal treatment.
    Keywords:  Aspergillus fumigatus; Candida albicans; Phage; Sporothrix globosa; fungi
    DOI:  https://doi.org/10.1080/1040841X.2025.2572805
  12. Eur J Pharm Biopharm. 2025 Oct 15. pii: S0939-6411(25)00271-1. [Epub ahead of print] 114894
       INTRODUCTION: Chronic wounds are injuries that persist beyond expected healing timeframes. Although they have varying aetiologies, abnormal development, prolonged inflammation and evident hypoxia are common features in all chronic wounds. Innovative treatments are sought and gas-based therapies in particular have shown promise in supporting conventional treatment strategies. This scoping review aims to identify and compare the range of formulations that are used for gas-based therapy and evaluate their effectiveness in treating chronic wounds.
    METHODS: A scoping review was conducted with articles identified from the Medline, Embase and Scopus databases. Articles exploring gas-based therapies in chronic wound healing were identified after screening all the search results against inclusion and exclusion criteria.
    RESULTS AND DISCUSSION: There were 54 clinical studies and 45 preclinical studies eligible for analysis. Gas-based therapies were delivered by various modalities. Hyperbaric oxygen therapy and topical gas therapies demonstrated some clinical utilisation, though adoption into standard care protocols was limited by costs and variable treatment outcomes. Novel formulations were of significant interest within the preclinical space, with micro- and nanoparticle systems and hydrogel scaffolds demonstrating an ability to effectively deliver various therapeutic gases and improve chronic injury outcomes in cell and animal-based models. However, the wound healing capacities of established and exploratory approaches have rarely been compared to each other.
    CONCLUSIONS: Hyperbaric oxygen therapy and topical gas therapy are clinically used in chronic wound management, although they have not been adopted as part of standard wound care. A variety of recently developed gas-loaded formulations have demonstrated preclinical potential and are poised to soon migrate into the clinical trial domain.
    Keywords:  Chronic wounds; Drug delivery; Formulation; Therapeutic gases; Wound healing
    DOI:  https://doi.org/10.1016/j.ejpb.2025.114894
  13. Adv Healthc Mater. 2025 Oct 13. e03113
      Multiple drug-resistant bacteria are a growing life-threatening problem and novel treatment strategies are urgently needed. One promising option is the use of lytic bacteriophages, viruses that infect and kill bacteria with high specificity. To efficiently utilize bacteriophage therapy for the treatment of implant-associated infections, an effective strategy for the local, long-lasting administration of bacteriophages at the site of infection is required. With the aim of developing a defined delivery system, this study investigates the feasibility of 3D extrusion printing of bacteriophages embedded in biomaterial inks by using a Staphylococcus aureus-specific phage strain as model. It is demonstrated that a bacteriophage-loaded hydrogel blend consisting of alginate and methylcellulose (AlgMC) can be printed with high shape fidelity. After cross-linking, the hydrogel constructs release bacteriophages that maintain their activity against S. aureus over a period of 35 days when incubated in human-plasma-like medium (HPLM). The integration of the nanoclay Laponite into the AlgMC blend, known for its high binding capacity for biomolecules, does not further prolong the release under (near) physiological conditions in HPLM but may protect bacteriophages under nonphysiological conditions. In conclusion, bacteriophage-loaded AlgMC inks fulfill the requirements for local bacteriophage therapy as they release active bacteriophages in a sustained manner.
    Keywords:  3D extrusion‐printing; Staphylococcus aureus; alginate; bacteriophages; implant‐associated infections; laponite; methylcellulose
    DOI:  https://doi.org/10.1002/adhm.202503113
  14. Nanomaterials (Basel). 2025 Oct 09. pii: 1537. [Epub ahead of print]15(19):
      We engineer an enhanced three-dimensional (3D) adipose model by integrating mesoporous silica (mSiO2) nanoparticles into human adipose-derived stem cell spheroids. The mSiO2 is highly cytocompatible, enables stable dispersion, and yields spheroids that preserve structural integrity and roundness for at least 14 days, accompanied by higher metabolic activity and reduced hypoxic stress. Under adipogenic induction, the nanoparticles embedded spheroids exhibit deeper lipid accumulation and increased expression of PPARγ, adiponectin, and FABP4. As a proof of concept, we leveraged this 3D platform to examine phage uptake and tissue-level distribution in adipose spheroids in comparison with conventional 2D cultures. These experiments reveal that both the cellular differentiation state and the tissue architecture govern phage association and uptake. Together, our findings indicate that phages engage mammalian cells beyond their bacterial hosts, a consideration that should inform future phage therapy design with implications for innate immune responses and overall therapeutic efficacy.
    Keywords:  3D spheroids; adipogenesis; bacteriophage T4; human adipose-derived stem cells; mesoporous silica nanoparticles
    DOI:  https://doi.org/10.3390/nano15191537
  15. Biomater Adv. 2025 Sep 30. pii: S2772-9508(25)00358-9. [Epub ahead of print]180 214531
      Antimicrobial resistance (AMR) poses a critical global health challenge, contributing to an estimated 1.27 million deaths worldwide due to bacterial infections in 2019. Phages offer a possible solution to this, but alone have been found to be sub-optimal. There can however be great benefits in combining antibiotics and phages to give synergistic treatment. To that end, this study incorporates both ciprofloxacin (cipro) and phages into co-loaded microparticles prepared by electrospraying (ES). With optimized concentrations (0.25 wt% cipro and 50 % v/v phage stock), the resulting phage encapsulation efficiency (EE) reached 29 ± 3 %. Following electrospraying, a modest reduction in phage titer was observed, from 5 × 107 to 1.4 × 107 PFU/mg, suggesting good preservation of phage viability during the electrospraying process. The cipro loading reached 0.20 ± 0.01 %, with an EE of 79.9 ± 2.2 %. In addition to spherical morphology and efficient phage loading, the particles exhibited a rapid initial release of their therapeutic cargo, achieving 98.8 ± 4.0 % of phage release and 93.5 ± 7.0 % of cipro release within 10 min. The combination of half the minimum heat inhibition concentration (MHIC) of cipro (0.3 μg/ml) and 108 PFU/ml phages completely inhibited the growth of Pseudomonas aeruginosa (P. aeruginosa) over 30 h, and a co-loaded particle concentration of 333 μg/ml extended bacterial inhibition for over 40 h. The results provide meaningful guidance for the design and optimization of antibiotic- and phage-loaded microparticles as potential antibacterial formulations for the treatment of bacterial infections.
    Keywords:  Anti-microbial resistance; Ciprofloxacin; Drug delivery; Electrospraying; Phages
    DOI:  https://doi.org/10.1016/j.bioadv.2025.214531
  16. Int J Food Microbiol. 2025 Oct 02. pii: S0168-1605(25)00415-5. [Epub ahead of print]445 111470
      Salmonella contamination of eggs poses a significant public health risk, contributing to foodborne illnesses worldwide and necessitating effective control measures to ensure food safety. Although chemical sanitization followed by refrigeration has been widely recommended to control bacterial contamination, it has limitations, including concerns over chemical residues, microbial resistance, and practical constraints in regions with limited cold-chain infrastructure. Bacteriophages are a promising alternative because of their specificity and ability to infect and lyse bacterial hosts. However, the application of phages to eggshells is hindered by rapid desiccation, which reduces their efficacy over time. In this study, we developed a bacteriophage-mineral oil emulsion to improve phage stability and enhance the antimicrobial efficacy on eggshell surfaces. A lytic Salmonella phage, pSe_SNUABM_01, was isolated, characterized, and incorporated into a mineral oil-based emulsion. The formulation was optimized by adjusting the oil-to-water ratio, mixing speed and emulsification duration. The 4:6 (v/v) oil-to-water ratio at 3000 rpm for 7 min demonstrated the highest stability after 21 days. On eggshell surfaces, the phage-emulsion coating significantly reduced Salmonella loads compared to untreated and conventionally coated eggs and maintained antibacterial activity over time. The emulsion also covered eggshell pores and cracks, thereby mitigating bacterial penetration. These findings suggest that phage emulsion coating could serve as a practical and effective strategy for reducing Salmonella contamination in eggshells, particularly in settings where refrigeration is not feasible. This approach combines physical protection with targeted antimicrobial activity, providing a viable alternative to conventional methods.
    Keywords:  Antimicrobial coating; Food additive; Food safety; Foodborne pathogen; Phage therapy
    DOI:  https://doi.org/10.1016/j.ijfoodmicro.2025.111470
  17. Eur J Med Res. 2025 Oct 14. 30(1): 971
      Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multiorgan involvement, with pathogenesis closely linked to that of gut dysbiosis and metabolic disturbances. Studies indicate that SLE patients exhibit significantly reduced gut microbial diversity, increased abundance of pathogenic bacteria, and decreased beneficial bacteria. Dysbiosis exacerbates disease progression by disrupting the intestinal barrier, triggering autoimmune responses, and promoting proinflammatory cytokine release. Metabolomic analyses further reveal that SLE is associated with dysregulated amino acid metabolism, reduced short-chain fatty acids, and disrupted lipid homeostasis, which correlate with disease activity, renal injury, and increased atherosclerosis risk. Emerging microbiota-targeted interventions, such as fecal microbiota transplantation (FMT), probiotics/prebiotics, phage therapy, and dietary modifications, demonstrate promising therapeutic potential by restoring microbial balance, enhancing immune regulation, and improving metabolic homeostasis. This review systematically summarizes the alterations in gut microbiota and metabolism in SLE, their critical roles in disease progression, diagnosis, and pathogenesis, and explores the clinical value of microbial-targeted strategies in improving SLE outcomes.
    Keywords:  Diagnosis and treatment; Gut microbiota; Metabolomics; Systemic lupus erythematosus; Therapeutic strategies
    DOI:  https://doi.org/10.1186/s40001-025-03264-1
  18. Appl Environ Microbiol. 2025 Oct 14. e0126925
      The human gut is a dynamic ecosystem where bacteriophages (phages) and bacteria interact within a complex mucosal environment. Here, we introduce the concept of mucofilm, a hybrid matrix composed of mucus produced by host cells and bacterial biofilm, as a unified ecological niche in the gut while also recognizing its relevance to other mucus-covered surfaces. Traditionally treated as separate entities, mucus and biofilm are in fact deeply interwoven, forming a complex environment that shapes microbial interactions, phage dynamics, and host responses. We question whether traditional knowledge about phage-biofilm interactions is transferable to mucofilm, and we therefore believe that recognizing mucofilm as a distinct structure is essential for understanding how phages interact with the gut microbiome, influencing microbial resilience, diversity, and immune modulation. This commentary challenges conventional compartmentalization and highlights the need to consider mucofilm as a single, integrated system when designing microbiome and phage-related studies. By doing so, we can better predict microbial behavior and improve therapeutic strategies targeting gut-associated diseases.
    Keywords:  bacteriophage-bacterial interactions; bacteriophages; biofilm; gut ecology; human gut microbiome; reservoir; resilience; spatial distribution
    DOI:  https://doi.org/10.1128/aem.01269-25
  19. Front Microbiol. 2025 ;16 1621267
      Pectobacterium brasiliense causes soft rot in many economically important crops, including vegetables and ornamentals, leading to significant yield losses. Traditional antibiotics, bactericides, and antimicrobial agents face limitations such as bioaccumulation on plants and the emergence of microbial resistance. Bacteriophages (phages) offer a promising alternative for effective control of a variety of phytopathogens. In this study, we isolated and characterized a virulent phage as a potential biocontrol agent against P. brasiliense. The phage was designated as PbrM1EGY, as it specifically targets only tested strains of P. brasiliense (Pbr) and is the first Myoviridae phage (M1) isolated from Egypt (EGY). The phage has an icosahedral head measuring 46.3 ± 3.9 nm and a long, contractile tail of 99.9 ± 3.9 nm. Phage PbrM1EGY exhibited relative stability across a wide range of environmental conditions, including pH (3 to 11), temperatures (4-50°C), NaCl concentrations (1-15%), and ultraviolet light exposure (1-15 min). It takes about 50 min for PbrM1EGY to complete its lytic cycle with a latent period of approximately 20 min and an average burst size of 749 ± 40 PFU per infected cell. At MOIs of 0.01, 0.1 and 1, phage PbrM1EGY significantly reduced the in vitro growth of P. brasiliense compared to the bacterial control without phage treatment. When tested in planta, the phage effectively prevented the development of soft rot symptoms in pepper and cucumber fruits, carrot roots, and potato tubers, while significantly reducing tissue maceration in onion bulbs. Our findings suggest that phage PbrM1EGY has great potential as a biocontrol agent against soft rot disease caused by P. brasiliense in vegetable crops, including pepper, cucumber, carrot, onion and potato.
    Keywords:  bacteriophage; genome analysis; soft rot Pectobacteriaceae; soft rot suppression; stability
    DOI:  https://doi.org/10.3389/fmicb.2025.1621267
  20. Front Vet Sci. 2025 ;12 1679093
      Aeromonas hydrophila (A. hydrophila) is a common pathogen in aquaculture that also causes opportunistic infections and sporadic food- and water-borne illness in humans. Phage therapy is increasingly considered a promising complementary medicine for antibiotic therapy. In this study, we isolated a novel A. hydrophila phage (designated BUCT551) using A. hydrophila strain Ah18 as an indicator. The one-step growth curve demonstrated that BUCT551 had a latent period of 20 min and a burst size of 32 PFU/cell at its optimal multiplicity of infection (0.1). BUCT551 had a survival pH range from 5 to 10 and could tolerant temperatures from 4 °C to 50 °C. Host range analysis showed that the phage was able to lyse not only A. hydrophila, but also Aeromonas veronii. Whole-genome sequencing of BUCT551 revealed a linear DNA genome of 61,382 bp. Bioinformatics analysis demonstrated that the genome of phage BUCT551 contains 74 predicted open reading frames (ORFs), of which 27 were annotated as functional proteins with assigned biological roles. Notably, no lysogeny-associated genes, antimicrobial resistance determinants, virulence factors, or tRNA genes were identified in this phage genome. A comparative genomic analysis showed that phage BUCT551 is the closest relative to Aeromonas phage LAh_7 and shares the same new branch in the phylogenetic tree. Characterization of the phage BUCT551 enriches our knowledge about the diversity of A. hydrophila phages.
    Keywords:  Aeromonas hydrophila; Aeromonas veronii; drug resistant; genome analysis; phage BUCT551
    DOI:  https://doi.org/10.3389/fvets.2025.1679093
  21. Front Pharmacol. 2025 ;16 1653424
      The global rise of multidrug-resistant organisms (MDROs), such as carbapenem-resistant Enterobacteriaceae (CRE) and methicillin-resistant Staphylococcus aureus (MRSA), has rendered conventional antibiotics increasingly ineffective, particularly in intensive care units (ICUs) where mortality rates exceed 50% in severe infections. Overuse of broad-spectrum antibiotics accelerates resistance while disrupting host microbiota, necessitating innovative "antibiotic-sparing" strategies. This review synthesizes three pillars of intervention: (1) non-antibiotic therapies, including bacteriophages for targeted pathogen lysis, monoclonal antibodies (e.g., BiS4αPa against Pseudomonas aeruginosa), and nanotechnology-enhanced antimicrobial peptides (AMPs) for biofilm disruption; (2) antimicrobial stewardship integrating rapid diagnostics (MALDI-TOF, mNGS), PK/PD-guided dosing, and short-course regimens (7-day therapy validated by RCTs); and (3) transmission prevention through UV-C disinfection, AI-driven hygiene compliance, and gut microbiota modulation. Key innovations include phage-antibiotic synergies, bispecific antibody engineering, and dynamic PK/PD-TDM frameworks. Despite challenges in clinical translation and cost-effectiveness, these strategies collectively reduce antibiotic reliance, mitigate resistance evolution, and offer a paradigm shift toward precision infection control. Future directions emphasize combinatorial therapies, regulatory harmonization, and scalable environmental-behavioral interventions to address the post-antibiotic era crisis.
    Keywords:  MDROs; antibiotic-sparing; antimicrobial stewardship; infection; non-antibiotic therapies
    DOI:  https://doi.org/10.3389/fphar.2025.1653424
  22. Nature. 2025 Oct 15.
      Large-scale metagenomic and data-mining efforts have revealed an expansive diversity of bacteriophages (phages) within the human gut1-3. However, functional understanding of phage-host interactions within this complex environment is limited, largely due to a lack of cultured isolates available for experimental validation. Here we characterize 134 inducible prophages originating from 252 human gut bacterial isolates using 10 different induction conditions to expand the experimentally validated temperate phage-host pairs originating from the human gut. Importantly, only 18% of computationally predicted prophages could be induced in pure cultures. Moreover, we construct a 78-member synthetic microbiome that, when co-cultured in the presence of human colonic cells (Caco2), led to the induction of 35% phage species. Using cultured isolates, we demonstrate that human host-associated cellular products may act as induction agents, providing a possible link between gastrointestinal cell lysis and temperate phage populations4,5. We provide key insights into prophage diversity and genetics, including a genetic pathway for domestication, finding that polylysogeny was common and resulted in coordinated prophage induction, and that differential induction can be influenced by divergent prophage integration sites. More broadly, our study highlights the importance of culture-based techniques, alongside experimental validation, genomics and computational prediction, to understand the biology and function of temperate phages in the human gut microbiome. These culture-based approaches will enable applications across synthetic biology, biotechnology and microbiome fields.
    DOI:  https://doi.org/10.1038/s41586-025-09614-7
  23. Clin Podiatr Med Surg. 2025 Oct;pii: S0891-8422(25)00062-X. [Epub ahead of print]42(4): 635-645
      This article aims to guide practitioners through the evolving field of wound therapies, highlighting recent innovations with positive outcomes and potential. Therapies surveyed include silver products, negative pressure wound therapy, oxygen therapies (including hyperbaric oxygen and topical oxygen therapy), and skin substitutes. The article summarizes the benefits and risks associated with each and provides practical advice on their use for practitioners.
    Keywords:  Hyperbaric oxygen; Limb salvage; Negative pressure; Silver; Skin substitute; Topical oxygen; Wound therapy
    DOI:  https://doi.org/10.1016/j.cpm.2025.06.003
  24. Front Endocrinol (Lausanne). 2025 ;16 1657928
      Diabetes has long been recognized as a significant global public health burden, with its complications posing serious threats to patient health and survival. Diabetic foot ulcer (DFU) is a common and severe complication of diabetes, and its prognosis is closely associated with diabetic foot infection. Diabetic foot infections (DFI) can lead to chronic, non-healing wounds and, in severe cases, may necessitate amputation. Microbial infection, the primary form of diabetic foot infections, disrupts the inflammatory and proliferative phases of DFU wound healing by forming biofilms and expressing virulence factors, ultimately contributing to the chronicity of DFU. Despite extensive research on DFU treatment, effective management remains a significant challenge due to its high susceptibility to microbial infection and frequent recurrence. This review integrates microbial infections with the physiological processes of wound healing to systematically elucidate the major pathogenic microorganisms associated with diabetic foot infections and their key pathogenic mechanisms in the healing process. In addition, we summarize current strategies for both systematic and individualized management of DFU. From etiology and pathological mechanisms to clinical treatment, this review provides new insights into the pathological mechanisms underlying chronic DFU and offers valuable guidance for clinical practice and scientific research.
    Keywords:  biofilm; diabetic foot ulcer; microbial infections; treatment strategies; virulence factors; wound healing
    DOI:  https://doi.org/10.3389/fendo.2025.1657928
  25. Diagnostics (Basel). 2025 Sep 24. pii: 2436. [Epub ahead of print]15(19):
      Background: Chronic and acute wounds are often colonized by polymicrobial biofilms, delaying healing and complicating treatment. Rapid, non-invasive detection of pathogenic bacteria is therefore crucial for timely and targeted therapy. This study investigated porphyrin-producing bacterial species using the handheld cureVision imaging system. Methods: In this study, 20 clinically relevant, porphyrin-producing bacterial species were cultured on δ-aminolevulinic acid (ALA)-supplemented agar and analyzed using the handheld cureVision imaging system under 405 nm excitation. Both Red-Green-Blue (RGB) and fluorescence images were acquired under ambient daylight conditions, and fluorescence signals were quantified by grayscale intensity analysis. Results: All tested species exhibited measurable red porphyrin-associated fluorescence, with the highest intensities observed in Klebsiella pneumoniae, Klebsiella oxytoca, Veillonella parvula, and Alcaligenes faecalis. A standardized detectability threshold of 0.25, derived from negative controls, enabled semi-quantitative comparison across species. Statistical analysis confirmed that the fluorescence intensities of all bacterial samples were significantly elevated compared to the control (Wilcoxon signed-rank test and sign test, both p < 0.001; median intensity = 0.835, IQR: 0.63-0.975). Conclusions: These results demonstrate that the cureVision system enables robust and reliable detection of porphyrin-producing wound bacteria, supporting its potential as a rapid, non-invasive diagnostic method for assessing wound colonization and guiding targeted clinical interventions.
    Keywords:  biofilm; chronic wounds; fluorescence; heme; imaging; porphyrins; wound diagnostics; wound-colonizing bacteria; δ-aminolevulinic acid
    DOI:  https://doi.org/10.3390/diagnostics15192436
  26. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2025 Oct 15. 39(10): 1351-1355
       Objective: To review the research progress of three-dimensional (3D) bioprinting technology for wound dressing design and preparation.
    Methods: The literature on 3D bioprinted wound dressings in recent years, both domestically and internationally, was retrieved. The core principles of 3D bioprinting technology, mainstream methods, and their applications in wound dressings design and preparation were summarized.
    Results: By leveraging precise spatial manipulation capabilities and multi-material integration, 3D bioprinting technology constructs the functionalized wound dressings with complex structures and bioactivity. These dressings primarily function across several dimensions: wound hemostasis, infection control, controlled drug release, and monitoring wound healing.
    Conclusion: Although 3D bioprinted wound dressings can promote wound healing through multiple dimensions, large-scale clinical validation is still lacking. Future efforts should further clarify their clinical value and scope of application to provide more efficient, precise, and patient-comfortable treatment options for refractory wounds .
    Keywords:  Three-dimensional bioprinting technology; research progress; wound dressings
    DOI:  https://doi.org/10.7507/1002-1892.202506040
  27. Mol Cell. 2025 Oct 16. pii: S1097-2765(25)00744-0. [Epub ahead of print]85(20): 3743-3759
      Bacteriophages impose significant evolutionary pressure on bacteria, driving the emergence of a diverse array of antiphage defense systems. A central player in many identified antiphage systems is nicotinamide adenine dinucleotide (NAD+). This review explores the multifaceted roles of NAD+ in bacterial immunity, from its function as an essential metabolite and substrate for enzymatic defense to its involvement in signal transduction pathways. We examine how antiphage systems manipulate NAD+ to block phage infection and, conversely, how phages employ counterdefense strategies targeting immune pathways that rely on NAD,+ or use NAD+ themselves to evade host immunity. Finally, we discuss the remarkable evolutionary conservation of these NAD+-centric immune actors and strategies in eukaryotic innate immunity. This highlights NAD+'s pivotal role in innate immunity across domains of life.
    Keywords:  NAD(+); antiphage defense; innate immunity; phage
    DOI:  https://doi.org/10.1016/j.molcel.2025.09.003
  28. Front Microbiol. 2025 ;16 1650028
      Acinetobacter baumannii is a multidrug-resistant (MDR) pathogen associated with nosocomial infections, sporadically detected in cystic fibrosis (CF) patients. Treatment of A. baumannii may be hindered by polysaccharide capsule production of some isolates and extended resistance to most antibiotics. In these fearsome cases, colistin (COL) and cefiderocol (FDC) are considered last resort antibiotics. Unfortunately, resistance to these molecules is increasing. Indeed, we observed a hypermucoid (HM) A. baumannii strain producing OXA-23, isolated from a CF patient, rapidly evolving concomitant resistance to COL and FDC. At her first visit to our hospital, the 24-year-old female with a delayed CF diagnosis and advanced lung disease presented with one HM and one low mucoid (LM) A. baumannii phenotypes. Due to Pseudomonas aeruginosa infection, she received inhaled tobramycin and COL treatment. Five months later, two HM strains were isolated, with different susceptibility profiles to COL and FDC, one being completely resistant. Whole genome sequencing revealed that all four isolates, the initial HM and LM strains and the two subsequent HM strains, belonged to Sequence Type 2 and carried OXA-23 gene. Genetic distance revealed evolution from the same strain. HM strains carried mutations in genes involved in polysaccharide production while the resistant strain also harboured mutations conferring COL and FDC resistance. Biofilm production and motility of the four strains were evaluated to establish possible links between multiresistance, mucoidity and virulence. Phenotypic characterisation showed that HM strains lost some virulence traits during chronicisation and resistance development but likely persisted by exploiting the biofilm-mediated protection, maintaining both virulent and resistant subpopulations. We speculate that COL treatment forced A. baumannii resistance occurrence in a bacterial population already heteroresistant to FDC, resulting in a pan-resistant strain in this CF patient. Considering that lung transplantation still represents a life-saving option for CF patient with advanced lung disease, this study highlights the critical need for careful administration of last-resort molecules in patients that may face immunosuppression. Indeed, given the possibility of simultaneous emergence of resistance and the limited treatment options available to patients infected with MDR A. baumannii, last-resort antibiotics should be spared to avoid selection of pan-resistant microorganisms.
    Keywords:  Acinetobacter baumannii; cefiderocol; colistin; hypermucoid; multidrug-resistant; resistance
    DOI:  https://doi.org/10.3389/fmicb.2025.1650028
  29. Clin Podiatr Med Surg. 2025 Oct;pii: S0891-8422(25)00074-6. [Epub ahead of print]42(4): 647-656
      One of the most important fundamental cornerstones in treating diabetic foot ulcers involves offloading plantar pressure. Many dressings and devices have been developed with variable success rates secondary to design and patient adherence and tolerance of the designs. The current gold standard involves use of total contact casting or an irremovable cast walker. Following successful healing of a diabetic foot ulcer, devices such as custom orthotics and shoes are essential to reduce plantar pressures implicated in these wounds' recurrence.
    Keywords:  Diabetic foot ulcer; Diabetic inserts; Felted foam dressings; Offloading; Total contact cast; Ulcer healing
    DOI:  https://doi.org/10.1016/j.cpm.2025.06.015
  30. Case Rep Pulmonol. 2025 ;2025 5976252
      The incidence and mortality rate of lung abscess cases have declined significantly following the widespread introduction of broad-spectrum antibiotic therapy. Administration of antibiotics is considered the main treatment option, replacing invasive management, which currently is reserved only for selected patients. Four cases of patients with large lung abscesses analyzed in the article demonstrate the effectiveness of prolonged antibiotic therapy in the form of clinical improvement and regression of lesions imaged with computed tomography (CT) scans, in the absence of surgical drainage. However, the lack of a comparator group undergoing surgical interventions limits the ability to generalize the findings. The article highlights multiple diagnostic and management challenges clinicians face when treating complicated lung abscesses; however, the presented evidence is limited by a small sample size and lack of controls. Although the incidence of lung abscesses has dropped, they are still frequently seen in pulmonology, surgery, pediatrics, and internal medicine departments. In the face of the worldwide antimicrobial resistance crisis, the choice of effective antibiotic therapy remains a challenge, and there is no consensus on the duration of the treatment, as well as specific timing for introducing surgical intervention. As there are no high-quality recommendations or international studies evaluating the epidemiology of lung abscesses in the 21st century, further research seems necessary to help clinicians make appropriate therapeutic decisions.
    Keywords:  CT lesions; antibiotic therapy; lung abscess; lung infection; necrotic; pneumonia; resistance
    DOI:  https://doi.org/10.1155/crpu/5976252
  31. J Bacteriol. 2025 Oct 16. e0027925
      Staphylococcus aureus is a major opportunistic pathogen in humans and animals. More than 90% of human nasal S. aureus isolates carry Sa3int-phages that integrate into the bacterial hlb gene coding for a sphingomyelinase. Sa3int-phages encode highly human-specific virulence factors that enable S. aureus to adapt to the human host. Thus, balancing mechanisms are necessary for the phage-bacteria coexistence. However, the factors that coordinate these interactions have yet to be discovered. Here, we elucidate the impact of the DNA-binding protein SarA on the life cycle of two prototypic S. aureus phages, Sa3int Φ13 and Sa5int Φ11. SarA promotes the propagation of both phages, albeit via different mechanisms. SarA promotes Φ11 propagation by repressing the glycosyltransferase TarM, which affects the glycosylation pattern of the phage receptor, wall teichoic acid, thereby improving phage adsorption. SarA also dampens the DNA damage response as indicated by the downregulation of the ci and mor phage promoters and the umuC SOS target gene, as well as inhibition of Φ11 inducibility. For Φ13, however, SarA promotes phage replication rather than inhibiting phage induction. The replication-deficient phage Φ13K-rep was SarA-insensitive, and phage gene expression was unaltered in the sarA mutant. These results highlight SarA as a regulator of temperate phage propagation and support its role as a DNA structural protein that promotes phage replication.
    IMPORTANCE: The dynamic gain and loss of temperate phages is crucial for bacteria to adapt to specific niches. In Staphylococcus aureus Sa3int, phages are highly prevalent in human strains but are missing in most animal strains. The mechanisms that balance phage-bacteria coexistence are only partially understood. We demonstrate that the DNA-binding protein SarA is a key regulator of the phage life cycle. SarA protects bacteria from phage induction in response to DNA damage, yet it can also promote phage propagation by altering the phage receptor or interfering with phage replication. SarA likely functions not only as a transcriptional factor, but also as a bacterial chromosome structural component that controls the phage life cycle at different levels.
    Keywords:  DNA-binding proteins; Hlb; SOS-response; SarA; Staphylococcus aureus; phage
    DOI:  https://doi.org/10.1128/jb.00279-25
  32. Lancet Microbe. 2025 Oct 09. pii: S2666-5247(25)00124-7. [Epub ahead of print] 101196
       BACKGROUND: Parasites are foundational to ecosystem health both as indicator species of community productivity and as drivers of diversity. In bacterial communities, bacteriophage viruses can have such roles as they track and modulate the dynamic composition of bacterial hosts within an ecosystem. We aimed to test whether viromes can be used as broad signatures of microbiome health using previously published results across systems.
    METHODS: In this systematic review and meta-analysis, we searched PubMed, Google Scholar, Scopus, and Web of Science from Jan 22, 2022, to Sept 17, 2024, for peer-reviewed, primary literature published in English, using search terms "phage diversity", "microbiome", "virome", "virus", "phageome", "disease", and "dysbiosis". Inclusion criteria were: a comparison between a dysbiosis state and a healthy state in a human or animal host; a defined host organism and microbiome site; examination of the virome; an obtained measure of virome diversity (α, β, or both); use of statistical analysis to assess whether α or β diversity are changed in dysbiosis; and sufficient methodology description on viral isolation and on virus sequence analysis pipeline. We conducted a qualitative data analysis to assess factors explaining changes to virome diversity in dysbiosis. We then calculated response ratios for each study to test for overall patterns of virome α diversity change under disturbance. Finally, we conducted a quantitative analysis on studies from which we were able to obtain paired virome and bacteriome α diversity data to examine the correlation between these data in defined health compared with defined disturbance conditions. This study was not registered.
    FINDINGS: We identified a total of 74 studies for inclusion that spanned human (n=61), mouse (n=8), pig (n=3), dog (n=1), and cow (n=1) hosts and a diverse spectrum of infections and diseases. By comparing observed phage and bacterial diversity in microbiomes characterised by dysbiosis with those considered control populations, we were able to identify some key commonalities. Of the 69 studies that investigated changes to α diversity of the virome in dysbiosis, 28 (41%) reported significant changes, but with variable directional change. Of 38 datasets (from 30 studies) for which virome α diversity values were available, 22 (58%) gave a response ratio of less than 1 (α diversity decreases in dysbiosis) and 16 (42%) of more than 1 (α diversity increases in dysbiosis); however, in 27 (71%) datasets, 95% CIs overlapped with 1 (ie, no change in α diversity). We found shifting virome composition to be a more consistent signature of dysbiosis, with 47 (69%) of 68 studies reporting a significant change in viral β diversity with dysbiosis. 62 (89%) of 70 studies reported significant enrichment of system-specific viral taxa under dysbiosis. Our quantitative correlation analysis suggested that bacterial α diversity is a greater predictor of virome α diversity in healthy groups (mean r2=0·380; 95% CI 0·597-0·163) than in dysbiosis (mean r2=0·118, 0·223-0·012; sign test for asymmetric non-parametric data p=4·9 × 10-10).
    INTERPRETATION: Overall, although specific viral signatures of dysbiosis are likely to be highly disease-specific and condition-specific, we show that existing ecological theory shows promise in predicting the relationship between bacterial and phage diversity and in providing broad signatures of dysbiosis across disease systems. Our observation that the relationship between bacterial and phage diversity breaks down under disturbance suggests that this feature could be a useful signature of dysbiosis and that future studies incorporating the virome could provide opportunity to diagnose, treat, and better understand the causes of microbiome disturbance.
    FUNDING: There was no funding source for this study.
    DOI:  https://doi.org/10.1016/j.lanmic.2025.101196
  33. iScience. 2025 Oct 17. 28(10): 113557
      Plant disease outbreaks pose severe risks to global food security. Due to climate change, new diseases are expected to emerge, and the current use of chemical pesticides poses risks to environmental and human health. In the last decade, alternative plant protection agents of microbial origin have been developed, which also raise great expectations in the industry. Current products primarily represent individual microbial strains, either fungi or bacteria, which occasionally fail under field conditions due to various factors while their regulatory status differs globally. Recently, more diverse applications have started to emerge, ranging from microbial consortia, phages and protists to microbiome modulation or soil translocation. Integrated solutions, incorporating artificial intelligence are also proposed. In this review, we discuss the opportunities and challenges of these solutions, providing specific examples and discuss the regulatory needs for their market entry as well as their relevance for improving food security and planetary health.
    Keywords:  Agricultural science; Biological sciences; Biotechnology; Interaction of plants with organisms; Plant biology; Plant biotechnology
    DOI:  https://doi.org/10.1016/j.isci.2025.113557
  34. Folia Microbiol (Praha). 2025 Oct 11.
      The human oral microbiome is a complex, dynamic ecosystem critically involved in maintaining oral health and contributing to systemic well-being. Many bacteria and fungi are involved in oral cavities such as Penicillium, Rhodotorula, Saccharomycetales, Streptococcus, Veillonella, Neisseria, Actinomyces, and Schizophyllum. Disruption of microbial homeostasis, or dysbiosis, underpins a wide spectrum of oral diseases, including dental caries, periodontal disease, endodontic infections, and mucosal conditions. Recent advances in microbiome research have elucidated the mechanisms by which pathogenic microbial consortia, such as the red complex (Porphyromonas gingivalis, Tannerella. forsythia, and Treponema denticola), synergistically promote disease progression through virulence factors, metabolic interactions, and biofilm formation. Emerging microbiome-based therapies, comprising probiotics, postbiotics, predatory bacteria, and using bacteriophages, offer promising adjuncts or alternatives to traditional antimicrobial approaches by restoring microbial balance, reducing pathogenic load, and modulating host immune responses. For instance, probiotic strains like Streptococcus salivarius and Lactobacillus spp. have demonstrated efficacy in reducing plaque, gingival inflammation, and pathogenic bacteria, as well as having significant immunological modulation, while postbiotics provide similar benefits with enhanced safety and stability. Additionally, predatory bacteria such as Bdellovibrio bacteriovorus show potential for selective bacterial elimination and combating periodontal diseases that are driven by Gram-negative anaerobes. Bacteriophages offer another precision tool for targeting oral pathogens by lysing bacteria upon replication. Finally, oral microbiota transplantation aimed at treating periodontal disease by restoring a balanced microbial community in the oral cavity. These innovative strategies, combined with a nuanced understanding of biofilm dynamics and host-microbe interactions, pave the way for personalized and ecologically sustainable oral health interventions. Continued research is essential to translate these promising approaches into clinical practice, optimize delivery systems, and elucidate long-term safety and efficacy.
    Keywords:  Dental caries; Microbiota therapeutics; Oral diseases; Oral microbiome; Periodontal disease; Probiotics
    DOI:  https://doi.org/10.1007/s12223-025-01324-x